In March 2025, the Government of Canada announced a $62 million investment to build a 103,000-square-foot facility in Edmonton to scale up production of therapeutics and vaccines. The facility will develop genetic medicines able to target infections, rare diseases, and neurodegenerative conditions using a technology platform that improves targeting of treatments. It will also create approximately 90 new skilled jobs plus student co-op positions and strengthen Canada’s readiness for future health emergencies.